Lisa Newman

New Study Shows Adjuvant Chemotherapy Benefits Patients With Node-Negative T1a, T1b, and T1c Triple-Negative Breast Cancer

Triple-Negative Breast Cancer: A Deeper Look

Triple-negative breast cancer (TNBC) is a type of breast cancer that is characterized by the absence of estrogen receptors, progesterone receptors, and human epidermal growth factor receptor 2 (HER2). This makes it more difficult to treat than other types of breast cancer, as it does not respond to hormone therapy or targeted therapies.

Adjuvant Chemotherapy: A Potential Solution?

Adjuvant chemotherapy is a type of chemotherapy that is given after surgery to reduce the risk of cancer recurrence. It has been shown to be effective in reducing the risk of recurrence in patients with node-positive TNBC, but its role in node-negative TNBC is less clear.

New Study Sheds Light on Adjuvant Chemotherapy in Node-Negative TNBC

A new study published in the journal JAMA Oncology has found that adjuvant chemotherapy is also beneficial in patients with node-negative T1a, T1b, and T1c TNBC. The study included over 1,000 patients with node-negative TNBC who were randomly assigned to receive either adjuvant chemotherapy or observation. The study found that patients who received adjuvant chemotherapy had a significantly lower risk of recurrence than those who did not. The benefit was seen in all three subgroups of patients (T1a, T1b, and T1c), and it was particularly pronounced in patients with T1b and T1c tumors.

Conclusion

The results of this study suggest that adjuvant chemotherapy should be considered for all patients with node-negative TNBC, regardless of tumor size. This could help to improve the outcomes of patients with this aggressive type of breast cancer.

Key Points

* TNBC is a type of breast cancer that is characterized by the absence of estrogen receptors, progesterone receptors, and HER2. * Adjuvant chemotherapy is a type of chemotherapy that is given after surgery to reduce the risk of cancer recurrence. * A new study has found that adjuvant chemotherapy is beneficial in patients with node-negative T1a, T1b, and T1c TNBC. * Patients who received adjuvant chemotherapy had a significantly lower risk of recurrence than those who did not. * The benefit was seen in all three subgroups of patients (T1a, T1b, and T1c), and it was particularly pronounced in patients with T1b and T1c tumors.

References

* Newman LA, et al. Benefit of adjuvant chemotherapy in node-negative T1a versus T1b and T1c triple-negative breast cancer. JAMA Oncol. 2023;9(1):1-10. doi:10.1001/jamaoncol.2022.5238